Compare SPRO & TKNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPRO | TKNO |
|---|---|---|
| Founded | 2013 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 156.3M | 138.1M |
| IPO Year | 2017 | 2021 |
| Metric | SPRO | TKNO |
|---|---|---|
| Price | $2.20 | $5.07 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.6M | 208.7K |
| Earning Date | 05-13-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 111.81 | 43.86 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $66,802,000.00 | $40,520,000.00 |
| Revenue This Year | N/A | $8.27 |
| Revenue Next Year | $300.00 | $13.13 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 39.24 | 7.35 |
| 52 Week Low | $1.80 | $1.91 |
| 52 Week High | $3.09 | $6.68 |
| Indicator | SPRO | TKNO |
|---|---|---|
| Relative Strength Index (RSI) | 36.21 | 62.72 |
| Support Level | $2.19 | $4.79 |
| Resistance Level | $2.47 | $5.84 |
| Average True Range (ATR) | 0.26 | 0.49 |
| MACD | -0.07 | -0.03 |
| Stochastic Oscillator | 22.29 | 60.00 |
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
Alpha Teknova Inc provides critical reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Its offer three product types: pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It derives key revenue from United States.